Cardiovascular
β-Adrenergic blockers (β-blockers)
Drugs that block β receptors, slowing the heart and reducing its work and oxygen use; used in angina, after myocardial infarction, in hypertension and in heart failure.
Mécanisme d’action
- Blocking β1 receptors in the heart lowers heart rate and contractility and slows conduction through the sinoatrial and atrioventricular nodes.
- Cardiac output, workload and oxygen consumption fall, which relieves angina and protects the myocardium after infarction.
- Blood pressure falls through lower cardiac output, less renin release from the kidney and reduced sympathetic outflow.
- Non-selective drugs also block β2 receptors in the bronchi and blood vessels; cardioselective drugs mostly spare them, though only at lower doses.
Cibles moléculaires
- β1-adrenergic receptor (heart, kidney): Antagonist
- β2-adrenergic receptor (bronchi, vessels): Antagonist, with non-selective drugs
Médicaments : β-Adrenergic blockers (β-blockers)
Non-selective (β1 and β2)
- Propranolol (Non-selective: the prototype.)
Cardioselective (β1-selective)
- Metoprolol (Cardioselective (β1).)
- Atenolol (Cardioselective (β1).)
- Bisoprolol (Cardioselective; used in heart failure.)
- Esmolol (Intravenous, very short-acting.)
Mixed α and β blockers
- Carvedilol and labetalol (Block both α and β receptors.)
Indications thérapeutiques
- Chronic stable angina: cardioselective drugs are first-line
- After myocardial infarction, to protect against a second infarct
- Hypertension
- Chronic heart failure (bisoprolol, extended-release metoprolol)
- Supraventricular arrhythmias
- Cirrhosis with oesophageal varices: non-selective drugs (propranolol, nadolol) lower portal pressure and reduce first bleeds and deaths from bleeding
- Aortic dissection: lowering the heart rate and the force of ejection reduces the shear stress on the aortic wall
- Thyrotoxicosis such as Graves disease: controls tremor, palpitations and anxiety while antithyroid drugs take effect
Maladies traitées
Effets indésirables
- Bradycardia, which usually limits the dose
- Bronchoconstriction in susceptible people
- Fatigue, dizziness, depression and vivid dreams
- Cold extremities
- Sexual dysfunction
- Hypoglycaemia in people on insulin, with its warning signs masked
Contre-indications selon le terrain
- Bronchial asthma (Contre-indiqué): Blocking β2 receptors in the bronchi causes bronchospasm; cardioselective drugs lose their selectivity at higher doses.
- Emphysema (Avec précaution): They can worsen airflow obstruction; a cardioselective drug is preferred when one is needed.
- Phaeochromocytoma (Contre-indiqué): Blocking β2-mediated vasodilatation leaves the tumour’s catecholamines acting unopposed on α receptors: a dangerous rise in blood pressure. An α-blocker always comes first.
- Bradycardia or heart block (Contre-indiqué): They slow the heart and atrioventricular conduction further.
- Diabetes treated with insulin (Avec précaution): They mask the tremor and palpitations that warn of hypoglycaemia and slow recovery from it.
- Acute decompensated heart failure (Avec précaution): Reducing contractility worsens it; they are started only once the patient is stable.
Autres précautions et interactions
- Never stop them abruptly: withdrawal can precipitate severe arrhythmias.
Sujets liés
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 7, Adrenergic Antagonists, β-Adrenergic blocking agents
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 10, Adrenoceptor Antagonist Drugs, Clinical pharmacology of the beta-receptor-blocking drugs
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.